Influenza vaccine

Routine vaccination:
    • Minimum age:
      • 6 months for trivalent inactivated influenza vaccine (IIV)
      • 2 years for live, attenuated influenza vaccine (LAIV)
    • IIV: Recommended only for the vaccination of persons with certain high-risk conditions.
    • LAIV: Recommended for only healthy children aged 2-18 years.
    • For most healthy children aged 2 through 18 years, either LAIV or IIV may be used.
    • LAIV should NOT be administered to following category of children:
      • Who have experienced severe allergic reactions to LAIV, any of its components, or to a previous dose of any other influenza vaccine;
      • Children 2 through 17 years receiving aspirin or aspirin-containing products;
      • Children with immunodeficiency;
      • Children 2 through 4 years of age with asthma or who had wheezing in the past 12 months;
      • Children who have taken influenza antiviral medications in the previous 48 hours
      • Children who have experienced severe allergic reactions to LAIV, any of its components
    • IIV: First time vaccination: 6 months to below 9 years: two doses 1 month apart; 9 years and above: single dose
    • Annual revaccination with single dose.
    • LAIV: 2- 9 years: One or two doses as per the ACVIP annual recommendations; 9 years and above: single dose
    • Dosage:
    • IIV : aged 6–35 months 0.25 ml; 3 years and above: 0.5 ml
    • LAIV: see product insert of the available formulation
    • For the 2016-17 season, since the A (H3N2) and B flu viruses have drifted, a child who has received two doses of influenza vaccine (IIV or LAIV) should receive one dose, and those who have received one dose in previous season should receive two doses of new formulation at least 4 week apart. The two doses need not have been received during the same season or consecutive seasons.
    • For children aged 6 months through 8 years: Administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time.
    • All the currently available IIVs in the country contain the 'Swine flu' or 'A (H1N1)' antigen; no need to vaccinate separately.
    • LAIV: Not recommended for children with chronic medical conditions
    • ACVIP does not endorse the superiority of LAIV over the IIV. There is not adequate data available from the country to recommend discontinuation of LAIV use in healthy individuals contrary to recent CDC ACIP recommendations.
    • Best time to vaccinate:
      • As soon as the new vaccine is released and available in the market o Just before the onset of rainy season.
      • Some regions may consider vaccination just prior to onset of winters based on local epidemiology data